868860-22-4Relevant academic research and scientific papers
PHOTOAFFINITY PROBES
-
Page/Page column 22; 73; 90-91, (2020/10/09)
Provided herein are compositions and methods for photoaffinity labeling of molecular targets. In particular, probes that specifically interact with cellular targets based on their affinity and are then covalently linked to the cellular target via a photor
Pyrazolopyrimidines as dual Akt/p70S6K inhibitors
Rice, Kenneth D.,Kim, Moon H.,Bussenius, Joerg,Anand, Neel K.,Blazey, Charles M.,Bowles, Owen J.,Canne-Bannen, Lynne,Chan, Diva S.-M.,Chen, Baili,Co, Erick W.,Costanzo, Simona,Defina, Steven C.,Dubenko, Larisa,Engst, Stefan,Franzini, Maurizio,Huang, Ping,Jammalamadaka, Vasu,Khoury, Richard G.,Klein, Rhett R.,Laird, A.Douglas,Le, Donna T.,Mac, Morrison B.,Matthews, David J.,Markby, David,Miller, Nicole,Nuss, John M.,Parks, Jason J.,Tsang, Tsze H.,Tsuhako, Amy L.,Wang, Yong,Xu, Wei
scheme or table, p. 2693 - 2697 (2012/05/20)
Activation of the PI3K/Akt/mTOR kinase pathway is frequently associated with human cancer. Selective inhibition of p70S6Kinase, which is the last kinase in the PI3K pathway, is not sufficient for strong tumor growth inhibition and can lead to activation of upstream proteins including Akt through relief of a negative feedback loop. Targeting multiple sites in the PI3K pathway might be beneficial for optimal activity. In this manuscript we report the design of dual Akt/p70S6K inhibitors and the evaluation of the lead compound 11b in vivo, which was eventually advanced into clinical development.
High-triplet-energy dendrons: Enhancing the luminescence of deep blue phosphorescent iridium(III) complexes
Lo, Shih-Chun,Harding, Ruth E.,Shipley, Christopher P.,Stevenson, Stuart G.,Burn, Paul L.,Samuel, Ifor D. W.
supporting information; experimental part, p. 16681 - 16688 (2010/04/04)
Solution-processable blue phosphorescent emitters with high luminescence efficiency are highly desirable for large-area displays and lighting applications. This report shows that when a fac-tris[1-methyl-5-(4-fluorophenyl) -3-n-propyl-1H-[1,2,4]triazolyl]
PHTHALAZINE DERIVATIVES
-
Page/Page column 126, (2008/12/05)
The present invention relates to novel phthalazine derivatives and, more particularly, to phthalazine derivatives that are useful as protein kinase inhibitors. The invention also relates to methods of preparing the compounds, compositions containing the compounds, and methods of treatment using the compounds.
